Considerations regarding maintenance therapy for acute myeloid leukemia in remission

References

• Maffini E, Ursi E, Barbato F, et al. The prevention of disease relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia. Front Oncol. 2022 Nov 30;12: 1066285. (Of interest in confronting the issues that limit effective use of therapies after allotransplant).
   Web of Science ®Google Scholar
• Abou Dalle I, El Cheikh J, Bazarbachi A. Pharmacologic strategies for post-transplant maintenance in acute myeloid leukemia: it is time to consider! Cancers (Basel). 2022;14(6):1490. doi: 10.3390/cancers14061490
   PubMed Web of Science ®Google Scholar
• Manobianco SA, Rakiewicz T, Wilde L, et al. Novel mechanisms for post-transplant maintenance therapy in acute myeloid leukemia. Front Oncol. 2022 Jul 12;12:892289. Sec. Hematologic Malignancies( of interest in considering new ideas for maintaining remission).
   PubMed Web of Science ®Google Scholar
• Babakhanlou R, Ravandi-Kashani F. SOHO State of the art updates and next questions |The role of maintenance therapy in acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. Clin Lymphoma Myeloma Leukemia. 2023 Jan;23(1):1–7. ( of interest as an overview of the problem of maintenance therapy for AML). doi: 10.1016/j.clml.2022.11.003
   PubMed Web of Science ®Google Scholar
• Zeiser R, Beelen DW, Bethge W, et al. Biology-driven approaches to prevent and treat relapse of myeloid neoplasia after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2019 Apr;25(4):e128–e140
   PubMedGoogle Scholar
• De Lima M, Roboz GJ, Platzbecker U, et al. AML and the art of remission maintenance. Blood Rev. 2021 Sep; 49:100829. EPUB 2021 Mar 24. doi: 10.1016/j.blre.2021.100829
   PubMed Web of Science ®Google Scholar
• Wei AH, Döhner H, Pocock C, et al. For the QUAZAR AML-001 trial investigators. Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission. N Engl J Med. 2020;383:2526–2537. ( Of considerable interest as the first demonstration in randomized trial that confirmed the efficacy of oral maintenance therapy).
   PubMed Web of Science ®Google Scholar
• Beauvais D, Wattebled KJ, Drumez E, et al. Commentary: maintenance with hypomethylating agents after allogeneic stem cell transplantation in acute myeloid leukemia and myelodysplastic syndrome: a systematic review and meta-analysis. Front Med. 2022 Oct 31;9. doi:10.3389/fmed.2022.1051526
   Web of Science ®Google Scholar
• Gunes EK, Ozkurt ZN, Yildiz S, et al. Comparison of maintenance regimens in acute promyelocytic leukemia patients. Leuk Res. 2023 Mar 2;128:107055.
   PubMed Web of Science ®Google Scholar
• Roboz GJ, Ravandi F, Wei AW, et al. Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status. Blood. 2022 Apr 7;139(14):2145–2155. doi: 10.1182/blood.2021013404
   PubMed Web of Science ®Google Scholar
• Wei AH, Döhner H, Sayar H, et al. Long-term survival with oral azacitidine for patients with acute myeloid leukemia in first remission after chemotherapy: updated results from the randomized, placebo-controlled, phase 3 QUAZAR AML-001 trial. Am J Hematol. 2023 Apr;98(4):E84–E87
   PubMed Web of Science ®Google Scholar
• Morin S, Giannotti F, Mamez AC, et al. Real-world experience of sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for FLT3-ITD AML reveals high rates of toxicity-related treatment interruption. Front Oncol. 2023 Mar 15;13:1095870. Sec. Hematologic Malignancies. doi: 10.3389/fonc.2023.1095870
   Web of Science ®Google Scholar
• Bazarbachi A, Labopin M, Battipaglia G. et. Allogeneic stem cell transplantation for FLT3-mutated acute myeloid leukemia: in vivo t-cell depletion and posttransplant sorafenib maintenance improve survival. A retrospective acute leukemia working party-european society for blood and marrow transplant study. Clin Hematol Int. 2019 Mar 18;1(1):58–74. eCollection 2019 Mar. doi: 10.2991/chi.d.190310.001
   PubMedGoogle Scholar
• Burchert A, Bug G, Fritz LV, et al. Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN). of interest as an early paper looking at targeted therapy in post-remission management of AML J Clin Oncol. 2020 Sep 10;38(26):2993–3002. Epub 2020 Jul 16. PMID: 32673171. doi:10.1200/JCO.19.03345
   PubMed Web of Science ®Google Scholar
• Bazarbachi A, Bug G, Baron F, et al. Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the acute leukemia working party of the European Society for Blood and Marrow Transplantation. Haematologica. 2020 Jun [cited 2020 Apr 2]. 105(6):1507–1516. doi: 10.3324/haematol.2019.243410
   PubMed Web of Science ®Google Scholar
• Fei X, Zhang S, Gu J, et al. FLT3 inhibitors as maintenance therapy post allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia patients with FLT3 mutations: a meta-analysis. Cancer Medicine. 2022 Nov 21;12(6):6877–6888. doi: 10.1002/cam4.5480
   PubMed Web of Science ®Google Scholar
• Andreas Burchert. Maintenance therapy for FLT3-ITD-mutated acute myeloid leukemia. Haematologica. 2021 Mar 1;106(3): 664–670. doi: 10.3324/haematol.2019.240747
   PubMed Web of Science ®Google Scholar
• Xuan L, Wang Y, Huang F, et al. Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial. Lancet Oncol. 2020 Sep;21(9):1201–1212
   PubMed Web of Science ®Google Scholar
• Maziarz RT, Levis M, Patnaik MM, et al. Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia. Bone Marrow Transplant. 2021 May;56(5):1180–1189
   PubMed Web of Science ®Google Scholar
• Arai Y, Chi SG, Minami Y, et al. FLT3-targeted treatment for acute myeloid leukemia. Int J Hematol. 2022 Sep;116(3):351–363
   PubMed Web of Science ®Google Scholar
• Perl AE, Larson RA, Podoltsev NA, et al. Follow-up of patients with R/R FLT3- mutation–positive AML treated with gilteritinib in the phase 3 ADMIRAL trial. Blood. 2022 Jun 9;139(23):3366–3375. doi: 10.1182/blood.2021011583
   PubMed Web of Science ®Google Scholar
• Stein EM, DiNardo CD, Fathi AT, et al. Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study. Blood. 2021 Apr 1;137(13):1792–1803. doi: 10.1182/blood.2020007233
   PubMed Web of Science ®Google Scholar
• Fathi AT, Kim HT, Soiffer RJ, et al. Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignancies. Blood Adv. 2022 Nov 22;6(22):5857–5865. doi: 10.1182/bloodadvances.2022008632
   PubMed Web of Science ®Google Scholar
• Bazinet A, Kantarjian H, Arani N, et al. Evolving trends and outcomes in older patients with acute myeloid leukemia including allogeneic stem cell transplantation. Am J Hematol. 2023;1383–1393:1–11.
   Google Scholar
• Weisdorf D. Allogeneic transplantation for advanced acute leukemia. Hematol Am Soc Hematol Educ Program. 2022 Dec 9;2022(1):534–538.
   PubMedGoogle Scholar
• Perna F, Espinoza-Gutarra MR, Bombaci G, et al. Immune-based therapeutic interventions for acute myeloid leukemia. Cancer Treat Res. 2022;183:225–254.
   PubMedGoogle Scholar
• Mohty M, El Hamed R, Brissot E, et al. New drugs before, during, and after hematopoietic stem cell transplantation for patients with acute myeloid leukemia. Haematologica. 2023 Feb 1;108(2):321–341. doi: 10.3324/haematol.2022.280798
   PubMed Web of Science ®Google Scholar
• Levis MJ, Hamadani M, Logan BR, et al. BMT CTN protocol 1506: a phase 3 trial of gilteritinib as maintenance therapy after allogeneic hematopoietic stem cell transplantation in patients with FLT3-ITD+ AML. Blood. 2019;134(Supplement_1):4602. doi: 10.1182/blood-2019-124322
   Google Scholar
• Erba HP, Montesinos P, Kim HJ, et al. QuANTUM-First Study Group; Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-first): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023 May 13 [cited 2023 Apr 25];401(10388): 1571–1583. doi: 10.1016/S0140-6736(23)00464-6
   PubMed Web of Science ®Google Scholar
• Jiang H, Liu XH, Kong J, et al. Interferon-α as maintenance therapy can significantly reduce relapse in patients with favorable-risk acute myeloid leukemia. Leukemia Lymphoma. 2021;62(12):2949–2956. doi: 10.1080/10428194.2021.1948027
   PubMed Web of Science ®Google Scholar
• Barbullushi K, Rampi N, Serpenti F, et al. Vaccination therapy for acute myeloid leukemia: where do we stand? Cancers (Basel). 2022;14(12):2994. doi: 10.3390/cancers14122994
   PubMed Web of Science ®Google Scholar
• Ho VT, Kim HT, Brock J, et al. GM-CSF secreting leukemia cell vaccination for MDS/AML after allogeneic HSCT: a randomized, double-blinded, phase 2 trial. Blood Adv. 2022 Apr 12;6(7):2183–2194. doi: 10.1182/bloodadvances.2021006255
   PubMed Web of Science ®Google Scholar
• Venugopala S, Xieb Z, Zeidan AM. An overview of novel therapies in advanced clinical testing for acute myeloid leukemia. Expert Rev Hematol. 2023. 2023;16(2):109–119. doi:10.1080/17474086.2023.2174521
   PubMed Web of Science ®Google Scholar